Fig. 1From: Enhanced IL-34 expression in Nivolumab-resistant metastatic melanomaIL-34 expression in Nivolumab-resistant metastatic melanoma. (a) Scheme showing the chronologic progression of disease and treatment procedures. (b) Representative data of immunohistochemistry staining of IL-34 or melanoma antigens in primary or Nivolumab-resistant metastatic melanomaBack to article page